Skip to main content
    O

    Oramed Pharmaceuticals Inc (ORMP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.90
    +0.19 (+5.12%)

    Market Cap: $161.33M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Oramed Pharmaceuticals Inc (ORMP) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Oramed Pharmaceuticals (ORMP) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Oramed Pharmaceuticals reported EPS of -$0.16, below the $0.43 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    60%(21/35)
    Avg Surprise
    +36.34%

    Upcoming Estimates

    Reports Mar 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.38
    Range$0.36 - $0.39
    3 analysts
    Revenue Consensus
    N/A
    RangeN/A
    3 analysts
    Reports May 17, 2027 (est.)Period ending Mar 31, 2027
    EPS ConsensusN/A
    RangeN/A
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    ORMP has an expected report date of Mar 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 52.0% above the $0.25 reported for the quarter ended Dec 31, 2025.

    Earnings History

    Of the 35 quarters below that had an estimate, ORMP beat 21, missed 12 and matched 2. The widest gap in the table came in the quarter ended Jun 30, 2025, when EPS landed 875.00% above the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.16$0.43$0.43 - $0.43-137.21%Miss-114.2%1N/ANov 12, 2026N/A
    Jun 30, 2026-$0.09$0.43$0.43 - $0.43-120.93%Miss-129.0%1N/AAug 10, 2026N/A
    Mar 31, 2026$0.91N/AN/AN/AN/AN/AN/AN/AMay 19, 2026N/A
    Dec 31, 2025$0.25-$0.08N/A+412.50%BeatN/A10 up, 0 downMar 26, 2026N/A
    Sep 30, 2025$1.13-$0.04-$0.04 - -$0.04N/AN/AN/A10 up, 0 downNov 13, 2025N/A
    Jun 30, 2025$0.31-$0.04N/A+875.00%Beat+40.9%N/A0 up, 0 downAug 14, 2025N/A
    Mar 31, 2025-$0.19-$0.03N/A-533.33%Miss-575.0%N/A0 up, 0 downMay 15, 2025$2.00M
    Dec 31, 2024-$0.26$0.02-$0.07 - $0.02N/AN/A-177.3%20 up, 0 downMar 27, 2025N/A
    Sep 30, 2024-$0.48-$0.02-$0.02 - $0.03N/AN/AN/A20 up, 0 downNov 7, 2024N/A
    Jun 30, 2024$0.22-$0.02-$0.02 - $0.04N/AN/AN/A20 up, 0 downAug 14, 2024N/A
    Mar 31, 2024$0.04$0.02$0.02 - $0.02+100.00%BeatN/A10 up, 0 downMay 9, 2024N/A
    Dec 31, 2023$0.33-$0.12-$0.23 - -$0.01+375.00%BeatN/A20 up, 0 downMar 6, 2024N/A
    Sep 30, 2023-$0.08-$0.09-$0.09 - -$0.08+11.11%BeatN/A20 up, 0 downNov 9, 2023N/A
    Jun 30, 2023-$0.03-$0.09-$0.12 - -$0.09+66.67%BeatN/A30 up, 0 downAug 10, 2023$674000
    Mar 31, 2023-$0.08-$0.25-$0.29 - -$0.23+68.00%BeatN/A20 up, 0 downMay 11, 2023$666000
    Dec 31, 2022-$0.22-$0.23-$0.32 - -$0.16+4.35%BeatN/A50 up, 0 downMar 6, 2023$681000
    Sep 30, 2022-$0.18-$0.26-$0.30 - -$0.20+30.77%BeatN/A60 up, 0 downNov 10, 2022$682000
    Jun 30, 2022-$0.27-$0.24N/A-12.50%MissN/AN/A0 up, 0 downAug 10, 2022$674000
    Mar 31, 2022-$0.27-$0.27N/A0.00%In lineN/AN/AN/AMay 12, 2022$666000
    Dec 31, 2021-$0.22-$0.16N/A-37.50%MissN/AN/AN/AJan 11, 2022$674000
    Sep 30, 2021-$0.21-$0.18N/A-16.67%MissN/AN/AN/ANov 24, 2021$683000
    Jun 30, 2021-$0.17-$0.24N/A+29.17%BeatN/AN/AN/AJul 14, 2021$681000
    Mar 31, 2021-$0.17-$0.17N/A0.00%In lineN/AN/AN/AApr 13, 2021$665000
    Dec 31, 2020-$0.23-$0.19N/A-21.05%MissN/AN/AN/AJan 14, 2021$674000
    Sep 30, 2020-$0.12-$0.21N/A+42.86%BeatN/AN/AN/ANov 24, 2020$681000
    Jun 30, 2020-$0.10-$0.20N/A+50.00%BeatN/AN/AN/AJul 7, 2020$681000
    Mar 31, 2020-$0.21-$0.17N/A-23.53%MissN/AN/AN/AApr 6, 2020$674000
    Dec 31, 2019-$0.15-$0.23N/A+34.78%BeatN/AN/AN/AJan 9, 2020$674000
    Sep 30, 2019-$0.13-$0.24N/A+45.83%BeatN/AN/AN/ANov 27, 2019$681000
    Jun 30, 2019-$0.23-$0.24N/A+4.17%BeatN/AN/AN/AJul 10, 2019$682000
    Mar 31, 2019-$0.21-$0.26N/A+19.23%BeatN/AN/AN/AApr 10, 2019$666000
    Dec 31, 2018-$0.25-$0.19N/A-31.58%MissN/AN/AN/AJan 14, 2019$674000
    Sep 30, 2018-$0.18-$0.29N/A+37.93%BeatN/AN/AN/ANov 28, 2018$617000
    Jun 30, 2018-$0.30-$0.27N/A-11.11%MissN/AN/AN/AJul 12, 2018$617000
    Mar 31, 2018-$0.20-$0.29N/A+31.03%BeatN/AN/AN/AApr 8, 2018$604000
    Dec 31, 2017-$0.18-$0.21N/A+14.29%BeatN/AN/AN/AJan 11, 2018$611000
    Sep 30, 2017-$0.20-$0.23N/A+13.04%BeatN/AN/AN/ANov 29, 2017$618000
    Jun 30, 2017-$0.15-$0.27N/A+44.44%BeatN/AN/AN/AJul 6, 2017$617000
    Mar 31, 2017-$0.24-$0.19N/A-26.32%MissN/AN/AN/AApr 5, 2017$611000
    Dec 31, 2016-$0.20-$0.12N/A-66.67%MissN/AN/AN/AJan 11, 2017$610000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.50, a profit after a loss of $0.48 per share the year before. It was -$0.86 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.50N/A
    Dec 31, 2024-$0.48-439.4%
    Dec 31, 2023$0.14N/A
    Dec 31, 2022-$0.94N/A
    Dec 31, 2021-$0.77N/A
    Dec 31, 2020-$0.66N/A
    Dec 31, 2019-$0.72N/A
    Dec 31, 2018-$0.93N/A
    Dec 31, 2017-$0.77N/A
    Dec 31, 2016-$0.86N/A

    Frequently Asked Questions About ORMP

    When is Oramed Pharmaceuticals's next earnings date?

    Oramed Pharmaceuticals's next earnings report is expected for Mar 24, 2027.

    Did ORMP beat earnings estimates last quarter?

    No. Oramed Pharmaceuticals reported EPS of -$0.16 for the quarter ended Sep 30, 2026, below the $0.43 estimate by 137.21%.

    What EPS do analysts expect from ORMP next quarter?

    The consensus EPS estimate for Oramed Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.38 from 3 analysts, with estimates from $0.36 to $0.39.

    How often does ORMP beat earnings estimates?

    Oramed Pharmaceuticals beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +122.77%.